AU5086699A - Methods for inhibiting tef-3 activity - Google Patents

Methods for inhibiting tef-3 activity Download PDF

Info

Publication number
AU5086699A
AU5086699A AU50866/99A AU5086699A AU5086699A AU 5086699 A AU5086699 A AU 5086699A AU 50866/99 A AU50866/99 A AU 50866/99A AU 5086699 A AU5086699 A AU 5086699A AU 5086699 A AU5086699 A AU 5086699A
Authority
AU
Australia
Prior art keywords
tef
cdna
cells
binding
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50866/99A
Other languages
English (en)
Inventor
Michael Howard Tindal
Richard Lee Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU5086699A publication Critical patent/AU5086699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU50866/99A 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity Abandoned AU5086699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9131898P 1998-06-30 1998-06-30
US60091318 1998-06-30
PCT/US1999/014829 WO2000000161A2 (en) 1998-06-30 1999-06-30 Methods for identification of tef-3 interacting factors

Publications (1)

Publication Number Publication Date
AU5086699A true AU5086699A (en) 2000-01-17

Family

ID=22227169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50866/99A Abandoned AU5086699A (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity

Country Status (7)

Country Link
EP (1) EP1089794A2 (no)
JP (1) JP2002519008A (no)
AU (1) AU5086699A (no)
CA (1) CA2332121A1 (no)
IL (1) IL140058A0 (no)
NO (1) NO20006198L (no)
WO (1) WO2000000161A2 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001906A1 (fr) * 2001-06-27 2003-01-09 Takeda Chemical Industries, Ltd. Procede de construction d'un modele animal de maladie des articulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824794A (en) * 1994-12-23 1998-10-20 Syntex (U.S.A.) Inc. Human stromelysin-1 promoter
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2270179A1 (en) * 1996-10-31 1998-05-07 Charles I. Rosenblum Assay and cell line for the identification of growth hormone mimetics
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs

Also Published As

Publication number Publication date
NO20006198D0 (no) 2000-12-06
IL140058A0 (en) 2002-02-10
CA2332121A1 (en) 2000-01-06
NO20006198L (no) 2001-02-28
WO2000000161A2 (en) 2000-01-06
WO2000000161A3 (en) 2001-01-04
JP2002519008A (ja) 2002-07-02
EP1089794A2 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
JP2002504818A (ja) リガンドファミリーのｎｔｎ−２メンバー
JP2009213490A (ja) 骨及び／又は関節疾患関連遺伝子
Madaio et al. Spontaneously produced anti‐DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells
JP2002514402A (ja) 腫瘍壊死因子レセプター放出酵素活性に影響を及ぼす因子
JP2000509967A (ja) カルシウムチャンネルモジュレーターとして活性のあるアセチルコリンエステラーゼの可溶形態からのペプチド
CA2344550A1 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JP2002536459A (ja) アテローム性動脈硬化症性病変の形成の阻害
US20110064704A1 (en) Ship-deficiency to increase megakaryocyte and platelet production
JP2002523078A (ja) 新規なｉｒａｐ−ｂｐポリペプチド及び核酸分子並びにこれらの利用法
JP2003517821A (ja) ２７８６、ヒトアミノペプチダーゼ
AU5086699A (en) Methods for inhibiting tef-3 activity
US20020102614A1 (en) Use of ZPR1 as a molecular probe for spinal muscular atrophy
JP2002534114A (ja) 新規ｌｒｓｇタンパク質および核酸分子ならびにそのための用途
PT90019B (pt) Processo para a preparacao e purificacao de factor de choque termico humano
JP2003523723A (ja) ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法
WO2002094842A2 (en) Control of myogenesis by modulation of p38 map kinase activity
JPH11506023A (ja) 新規ディスインテグリンメタロプロテアーゼおよび使用法
JP2002508934A (ja) Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド
JPH10502252A (ja) Ｄｐ−１及びその他のｄｐタンパク質の阻害剤のアッセイ
JP2003527831A (ja) エンドゼピン様ポリペプチドおよびエンドゼピン様ポリペプチドをコードするポリヌクレオチド
US20040213738A1 (en) CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
EP1613769A1 (en) Insulin-induced gene as therapeutic target in diabetes
AU3526400A (en) Methods and compositions for regulating memory consolidation
CN111139299A (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted